Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kevin Charles Gorman sold 105,983 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $80.25, for a total value of $8,505,135.75. Following the completion of the sale, the chief executive officer now directly owns 339,482 shares of the company’s stock, valued at $27,243,430.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kevin Charles Gorman also recently made the following trade(s):

  • On Tuesday, January 16th, Kevin Charles Gorman sold 3,750 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $78.89, for a total value of $295,837.50.

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at $79.28 on Friday. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $7,020.00, a P/E ratio of -35.71, a P/E/G ratio of 13.72 and a beta of 0.26. Neurocrine Biosciences, Inc. has a 52-week low of $39.21 and a 52-week high of $91.82.

Several brokerages have recently commented on NBIX. BidaskClub raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 31st. Deutsche Bank reissued a “buy” rating and issued a $79.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Citigroup reissued a “buy” rating and issued a $79.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Oppenheimer set a $95.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Monday, January 15th. Finally, Needham & Company LLC increased their price objective on Neurocrine Biosciences to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, January 16th. One research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Neurocrine Biosciences currently has an average rating of “Buy” and a consensus price target of $82.31.

Several institutional investors and hedge funds have recently modified their holdings of NBIX. The Manufacturers Life Insurance Company increased its position in shares of Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after acquiring an additional 193 shares during the last quarter. Crow Point Partners LLC purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $145,000. American International Group Inc. purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $161,000. M&T Bank Corp purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $202,000. Finally, Mission Wealth Management LP purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $204,000.

WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/neurocrine-biosciences-inc-nbix-ceo-sells-8505135-75-in-stock/1856449.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.